PHASE I,,
Healthy Adults,,
2025,"BMS CN0120012: A Phase 1, 4-part, Open-label Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adults Participants","BMS: A Phase 1, 4-part, Open-label Study to Evaluate the Effects of XXX Phenotypes on the Pharmacokinetics of Xanomeline Following XXX Administration in Healthy Adults Participants"
2025,"ENSHO THERAPEUTICS NSHO-101-HV202: A Phase 1 Study to Evaluate the Phannacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants","ENSHO THERAPEUTICS: A Phase 1 Study to Evaluate the Phannacokinetics, Safety, and Tolerability of XXX in Healthy Participants"
2025,"ABBVIE M24-931: A Phase 1 Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of XXXX","ABBVIE: A Phase 1 Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of XXXX"
2025,ABBVIE M24-920: A Phase 1 Pharmacokinetic Study in Healthy Subjects to Evaluate the Relative Bioavailability of Risankizumab Following Subcutaneous Administration with On-Body Injector,ABBVIE: A Phase 1 Pharmacokinetic Study in Healthy Subjects to Evaluate the Relative Bioavailability of XXX Following Subcutaneous Administration with On-Body Injector
2025,"ABBVIE M25-491: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous Doses of ABBV‑701 in Healthy Adult Western and Asian Subjects","ABBVIE: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous Doses of XXX in Healthy Adult Western and Asian Subjects"
2025,"GENFIT G1090N_P1_25_1: A Phase 1, Open-Label Study to Assess Pharmacokinetics, Safety, and Tolerability of G1090N in Healthy Subjects","GENFIT: A Phase 1, Open-Label Study to Assess Pharmacokinetics, Safety, and Tolerability of XXX in Healthy Subjects"
2025,"BMS CN0080026: A Phase 1, Randomized, Open-label, Parallel, Single-dose Study to Assess the Pharmacokinetics, Tolerability, and Absolute Bioavailability of Subcutaneous Administration of XXXX, an Anti-MTBR Tau Monoclonal Antibody, in Healthy Participants","BMS: A Phase 1, Randomized, Open-label, Parallel, Single-dose Study to Assess the Pharmacokinetics, Tolerability, and Absolute Bioavailability of Subcutaneous Administration of XXXX, an Anti-MTBR Tau Monoclonal Antibody, in Healthy Participants"
2025,"CELLARITY CLY124-HVS-101: A Phase 1, Randomized, Placebo-Controlled, Double Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX in Healthy Volunteers and Participants with Sickle Cell Disease","CELLARITY: A Phase 1, Randomized, Placebo-Controlled, Double Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX in Healthy Volunteers and Participants with Sickle Cell Disease"
2025,ELI LILLY J6H-MC-KXAA: A Single-Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of XXXX in Healthy Participants.,ELI LILLY: A Single-Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of XXXX in Healthy Participants.
,,
2025,"ELI LILLY AND COMPANY J4O-MC-EZHA: A single-ascending and multiple-ascending dose study of XXXX in healthy participants, participants with obesity and hypertension, and participants with decreased estimated glomerular filtration rate.","ELI LILLY AND COMPANY: A single-ascending and multiple-ascending dose study of XXXX in healthy participants, participants with obesity and hypertension, and participants with decreased estimated glomerular filtration rate."
2025,"ELI LILLY AND COMPANY J6E-MC-KWAC: A Phase 1 Study to Further Investigate the Pharmacokinetics, Safety and Tolerability, Food Effect and Drug-Drug Interaction of XXXX (XXX) in Healthy Participants","ELI LILLY AND COMPANY: A Phase 1 Study to Further Investigate the Pharmacokinetics, Safety and Tolerability, Food Effect and Drug-Drug Interaction of XXXX (XXX) in Healthy Participants"
2025,"GILEAD GS-US-683-6908: A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Volunteers and to Evaluate the Effect of Food and Acid-Reducing Agents on XXXX Pharmacokinetics","GILEAD: A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Volunteers and to Evaluate the Effect of Food and Acid-Reducing Agents on XXXX Pharmacokinetics"
2025,"GILEAD GS-US-671-6974: A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX, and the Effect of Food and Acid-Reducing Agents on the Pharmacokinetics and Pharmacodynamics of XXXX","GILEAD: A Phase 1 Study in Healthy Participants to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX, and the Effect of Food and Acid-Reducing Agents on the Pharmacokinetics and Pharmacodynamics of XXXX"
2025,"VISTERRA VIS954-102: A phase 1, randomized, placebo-controlled, double blind, multiple ascending dose trial to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of XXXX in healthy participants.","VISTERRA: A phase 1, randomized, placebo-controlled, double blind, multiple ascending dose trial to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of XXXX in healthy participants."
 ,,
2025,MERCK MK-7962: A Phase 1 Clinical Study in Healthy Females of Nonchildbearing Potential to Compare the Pharmacokinetics of XXXX (XXXX) Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation Cardiovascular,MERCK: A Phase 1 Clinical Study in Healthy Females of Nonchildbearing Potential to Compare the Pharmacokinetics of XXXX (XXXX) Administered as a Liquid Formulation in an Autoinjector Versus the Lyophilized Formulation Cardiovascular
2025,"GENENTECH GP44770: A Phase 1, Randomized, Two-Part, Parallel-Group Study to Assess the Bioequivalence of Subcutaneously Administered Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Subjects","GENENTECH: A Phase 1, Randomized, Two-Part, Parallel-Group Study to Assess the Bioequivalence of Subcutaneously Administered XXX Via Different Subcutaneous Delivery Platforms in Healthy Male Subjects"
2025,"VIATRIS INNOVATION GmbH ID-076-110:  Single-center, double-blind trial to assess the pharmacokinetics, the pharmacodynamics, and the tolerability of a single 16 mg dose of selatogrel (ACT-246475) in healthy Japanese and Caucasian participants","VIATRIS INNOVATION GmbH:  Single-center, double-blind trial to assess the pharmacokinetics, the pharmacodynamics, and the tolerability of a single 16 mg dose of XXX (XXX) in healthy Japanese and Caucasian participants"
2024,ABBVIE M24-342: A Phase 1 Pharmacokinetic Study in Healthy Subjects to Evaluate the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration with Prefilled Syringes,ABBVIE: A Phase 1 Pharmacokinetic Study in Healthy Subjects to Evaluate the Relative Bioavailability of Two Formulations of XXX Following Subcutaneous Administration with Prefilled Syringes
2024,"ABBVIE M25-527: A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Emraclidine in Healthy Adult Western, Japanese, and Han Chinese Subjects","ABBVIE: A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of XXX in Healthy Adult Western, Japanese, and Han Chinese Subjects"
2024,"ABBVIE M25-528: An Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Icalcaprant in Healthy Adult Japanese and Han Chinese Subjects","ABBVIE: An Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of XXX in Healthy Adult Japanese and Han Chinese Subjects"
2024,"ALLIANTHERA ATB102: A Phase I, Randomized, Placebo-Controlled, Sequential Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral YUQ-A1007 in Healthy Volunteers","ALLIANTHERA: A Phase I, Randomized, Placebo-Controlled, Sequential Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral XXX in Healthy Volunteers"
2024,"BMS CN0120030: Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of Dual-burst Release of Xanomeline with Immediate-Release Trospium Chloride versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity (Part 1) and an Open-label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Dual-burst Release of Xanomeline with Immediate-Release Trospium Chloride in Healthy Adult Participants (Part 2)","BMS: Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of Dual-burst Release of XXX with Immediate-Release XXX Chloride versus XXX in Healthy Adult and Elderly Participants of Japanese Ethnicity (Part 1) and an Open-label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Dual-burst Release of XXX with Immediate-Release XXX Chloride in Healthy Adult Participants (Part 2)"
2024,"BMS IM027-1035: An Open-label, Randomized, 2-Part, 4-Period, 2-Sequence, Fully Replicated Crossover Study to Assess the Comparative Bioavailability of BMS-986278 To-be-marketed Formulation Compared to the Phase 3 Clinical Trial Formulation in Healthy Participants","BMS: An Open-label, Randomized, 2-Part, 4-Period, 2-Sequence, Fully Replicated Crossover Study to Assess the Comparative Bioavailability of XXX To-be-marketed Formulation Compared to the Phase 3 Clinical Trial Formulation in Healthy Participants"
2024,"ECCOGENE EC0007: A Phase 1, Open Label, Fixed Sequence Study to Evaluate the Effect of XXXX on the Single Dose Pharmacokinetics of Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants","ECCOGENE: A Phase 1, Open Label, Fixed Sequence Study to Evaluate the Effect of XXXX on the Single Dose Pharmacokinetics of XXX, XXX, XXX and XXX in Healthy Participants"
2024,ELI LILLY AND COMPANY I6T-MC-AMCB: A Bioequivalence Study of Subcutaneous Injections of Citrate-Free XXXX solution Using a 1mL Autoinjector and an Investigational 2mL Autoinjector in Healthy Participants,ELI LILLY AND COMPANY: A Bioequivalence Study of Subcutaneous Injections of Citrate-Free XXXX solution Using a 1mL Autoinjector and an Investigational 2mL Autoinjector in Healthy Participants
2024,"GILEAD GS-US-200-5585: A Phase 1, Single-Dose Study to Evaluate the Pharmacokinetics (PK), Safety, and Tolerability of Oral Lenacapavir (LEN) in Healthy Japanese Participants","GILEAD: A Phase 1, Single-Dose Study to Evaluate the Pharmacokinetics (PK), Safety, and Tolerability of Oral XXX in Healthy Japanese Participants"
2024,"GILEAD GS-US-200-6718: A Phase 1a Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Different Formulations of Subcutaneous and/or Intramuscular XXXX in Healthy Participants","GILEAD: A Phase 1a Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Different Formulations of Subcutaneous and/or Intramuscular XXXX in Healthy Participants"
2024,"PFIZER C3421086: A Two-Part Phase 1, Open- Label, Fixed-Sequence Study to Evaluate the Multiple Dose Pharmacokinetics of Danuglipron Following Oral Administration and the Effects of Steady-State Danuglipron on the Pharmacokinetics of Single Oral Dose of Atorvastatin and Rosuvastatin in Otherwise Healthy Adult Participants with Overweight or Obesity","PFIZER: A Two-Part Phase 1, Open- Label, Fixed-Sequence Study to Evaluate the Multiple Dose Pharmacokinetics of XXX Following Oral Administration and the Effects of Steady-State XXX on the Pharmacokinetics of Single Oral Dose of XXX and XXX in Otherwise Healthy Adult Participants with Overweight or Obesity"
2024,"UCB UPO142: A Single-Center, Randomized, Investigator- And Participant-Blind, Placebo-Controlled, Phase 1 Study to Evaluate Safety, Tolerability, And Pharmacokinetics After a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants","UCB: A Single-Center, Randomized, Investigator- And Participant-Blind, Placebo-Controlled, Phase 1 Study to Evaluate Safety, Tolerability, And Pharmacokinetics After a Single Dose of XXX in Healthy Chinese and Japanese Participants"
2023,ABBVIE M24-696: A Phase 1 Pharmacokinetic Comparability Study in Healthy Subjects to Evaluate the Relative Bioavailability of Risankizumab Vials Manufactured by Two Different Processes,ABBVIE: A Phase 1 Pharmacokinetic Comparability Study in Healthy Subjects to Evaluate the Relative Bioavailability of Risankizumab Vials Manufactured by Two Different Processes
2023,"ONENESS FB825CLPK01: A Randomized, Placebo-Controlled, Double-Blind, Phase 1 Study to Evaluate the Safety and Bridging Pharmacokinetics Profile of XXXX for Single Subcutaneous Administration in Healthy Adults             ","ONENESS: A Randomized, Placebo-Controlled, Double-Blind, Phase 1 Study to Evaluate the Safety and Bridging Pharmacokinetics Profile of XXXX for Single Subcutaneous Administration in Healthy Adults             "
2023,"PFIZER C3421074: A Phase 1, Open-Label, Randomized Study with a 5-Period, 4-Sequence, Crossover Design to Compare the Single Dose P150harmacokinetics Between Immediate and Modified Release Formulations of XXXX Administered Orally to Healthy Adult Participants ","PFIZER: A Phase 1, Open-Label, Randomized Study with a 5-Period, 4-Sequence, Crossover Design to Compare the Single Dose P150harmacokinetics Between Immediate and Modified Release Formulations of XXXX Administered Orally to Healthy Adult Participants "
2023,"VIATRIS PERT-IJS-1001: A Randomized, Double-Blind, 3-arm Parallel Phase 1 Study to Assess Pharmacokinetics, Safety and Tolerability of XXXX Following a Single Dose of 420 mg Intravenous Infusion Compared to the EU and US Marketed Drug Product (Perjeta®) in Healthy Male Volunteers ","VIATRIS: A Randomized, Double-Blind, 3-arm Parallel Phase 1 Study to Assess Pharmacokinetics, Safety and Tolerability of XXXX Following a Single Dose of 420 mg Intravenous Infusion Compared to the EU and US Marketed Drug Product (Perjeta®) in Healthy Male Volunteers "
2022,ABBVIE M23-522: A Phase 1 Study in Healthy Subjects to Evaluate the Bioavailability of XXXX 150 mg/mL Formulation in the 180 mg Prefilled Syringe Relative to 90 mg/mL Formulation in the 90 mg Prefilled Syringe,ABBVIE: A Phase 1 Study in Healthy Subjects to Evaluate the Bioavailability of XXXX 150 mg/mL Formulation in the 180 mg Prefilled Syringe Relative to 90 mg/mL Formulation in the 90 mg Prefilled Syringe
2022,"BRISTOL-MYERS QUIBB IM032-030: An Open-Label, Single-Sequence, Crossover Study to Investigate the Interaction of Multiple Doses of XXXX at Steady State and Multiple Doses of a Combined Oral Hormonal Contraceptive (XXXX XXXX/XXXX) in Healthy Female Participants  ","BRISTOL-MYERS QUIBB: An Open-Label, Single-Sequence, Crossover Study to Investigate the Interaction of Multiple Doses of XXXX at Steady State and Multiple Doses of a Combined Oral Hormonal Contraceptive (XXXX XXXX/XXXX) in Healthy Female Participants  "
2022,"ABBVIE M20-974: Assessment of Multiple-Dose Pharmacokinetics and Safety of the Co-administration of XXXX, XXXX and XXXX, and Potential of XXXX for CYP3A Induction in Healthy Volunteers  ","ABBVIE: Assessment of Multiple-Dose Pharmacokinetics and Safety of the Co-administration of XXXX, XXXX and XXXX, and Potential of XXXX for CYP3A Induction in Healthy Volunteers  "
2022,"EISAI BAN-2401-A001-005: An Open-Label, Parallel-Group, Randomized Study to Demonstrate the Bioequivalence of the Subcutaneous Formulation of XXXX Supplied in Vials and a Single Use Auto-Injector","EISAI: An Open-Label, Parallel-Group, Randomized Study to Demonstrate the Bioequivalence of the Subcutaneous Formulation of XXXX Supplied in Vials and a Single Use Auto-Injector"
2022,"BRISTOL-MYERS SQUIBB IM042003: A Phase I, Open-Label, Randomized, Two-part Parallel Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of XXXX (also known as XXXX and XXXX) Administered using Autoinjector versus using Prefilled Syringe, and to Evaluate the Pharmacokinetics of XXXX When Administered by Autoinjector at Different Injection Sites, in Healthy Participants.","BRISTOL-MYERS SQUIBB: A Phase I, Open-Label, Randomized, Two-part Parallel Study to Compare the Pharmacokinetics of Single Subcutaneous Injections of XXXX (also known as XXXX and XXXX) Administered using Autoinjector versus using Prefilled Syringe, and to Evaluate the Pharmacokinetics of XXXX When Administered by Autoinjector at Different Injection Sites, in Healthy Participants."
2022,BRAINTREE BLI4700-103: Examination of Gastric Mucosal Abnormalities Before and After Bowel Preparation,BRAINTREE: Examination of Gastric Mucosal Abnormalities Before and After Bowel Preparation
2022,"PFIZER C1221007: A Phase 1, Open-Label, Randomized, Single Dose, 2-Way Crossover Study Assessing Pharmacokinetic Comparability Of Two XXXX Presentations, On-Body Injector And Prefilled Syringe, In Healthy Participants ","PFIZER: A Phase 1, Open-Label, Randomized, Single Dose, 2-Way Crossover Study Assessing Pharmacokinetic Comparability Of Two XXXX Presentations, On-Body Injector And Prefilled Syringe, In Healthy Participants "
2021,"AMGEN, INC. 20200359: An Open-Label, Randomized, Single-Dose, Parallel-Group Study in Healthy Subjects to Assess the Comparability of a Single Subcutaneous Dose of XXXX When Delivered Manually From A Prefilled Syringe Versus Delivered by an Autoinjector. ","AMGEN, INC.: An Open-Label, Randomized, Single-Dose, Parallel-Group Study in Healthy Subjects to Assess the Comparability of a Single Subcutaneous Dose of XXXX When Delivered Manually From A Prefilled Syringe Versus Delivered by an Autoinjector. "
2021,"BIOGEN 221HV103: A Randomized, Open-Label, Parallel-Arm Study to Assess the Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of XXXX (XXXX) Compared to a Single, Weight-Based Intravenous Dose in Healthy Volunteers. ","BIOGEN: A Randomized, Open-Label, Parallel-Arm Study to Assess the Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of XXXX (XXXX) Compared to a Single, Weight-Based Intravenous Dose in Healthy Volunteers. "
2021,"BIOGEN 271HV101: A Phase 1, Randomized, Blinded, Placebo-Controlled, Single and Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX in Healthy Adults. ","BIOGEN: A Phase 1, Randomized, Blinded, Placebo-Controlled, Single and Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX in Healthy Adults. "
2021,"CELGENE INTERNATIONAL RPC-1063-CP-005: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Active-Controlled (XXXX), Comparator-Controlled (XXXX), Multiple-Dose, Parallel-Group Study to Investigate the Pressor Effect of Oral XXXX During XXXX Treatment in Healthy Adult Subjects.","CELGENE INTERNATIONAL: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Active-Controlled (XXXX), Comparator-Controlled (XXXX), Multiple-Dose, Parallel-Group Study to Investigate the Pressor Effect of Oral XXXX During XXXX Treatment in Healthy Adult Subjects."
2021,"ELI LILLY & COMPANY J3E-MC-EZDA: A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Participants.   ","ELI LILLY & COMPANY: A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Participants.   "
2021,"GILEAD SCIENCES, INC. GS-US-563-6148: A Phase 1 Study to Evaluate the Potential Drug-Drug Interaction Between XXXX (XXX) and XXXX (XXX).","GILEAD SCIENCES, INC.: A Phase 1 Study to Evaluate the Potential Drug-Drug Interaction Between XXXX (XXX) and XXXX (XXX)."
2021,"GLAXOSMITHKLINE 213022: A Two-Part, Randomized, Double-Blind, Single-Dose, Crossover Study To Compare Formulations Produced By Two Methods Of Manufacture For Bioequivalence And Dissolution In Healthy Adult Volunteers            ","GLAXOSMITHKLINE: A Two-Part, Randomized, Double-Blind, Single-Dose, Crossover Study To Compare Formulations Produced By Two Methods Of Manufacture For Bioequivalence And Dissolution In Healthy Adult Volunteers            "
2020,"ABBVIE M19-128: A Phase 1, Pharmacokinetic Comparability Study of Intravenous and Subcutaneous Administration of XXXX in Healthy Subjects","ABBVIE: A Phase 1, Pharmacokinetic Comparability Study of Intravenous and Subcutaneous Administration of XXXX in Healthy Subjects"
2020,"ASTRAZENECA D822FC00008: A Phase I, Open-label, Randomized, Single-dose Study of XXXX in Healthy Subjects to Evaluate the Effect of Proton-pump Inhibitor (XXXX) on XXXX Capsule when Administered Orally with COCA-COLA. ","ASTRAZENECA: A Phase I, Open-label, Randomized, Single-dose Study of XXXX in Healthy Subjects to Evaluate the Effect of Proton-pump Inhibitor (XXXX) on XXXX Capsule when Administered Orally with COCA-COLA. "
 ,,
2020,"GENERON CORP. GC-652-03: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Male Subjects. ","GENERON CORP.: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Male Subjects. "
 ,,
2020,"GLAXOSMITHKLINE 209635: A Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to Determine the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX Administered Subcutaneously in Healthy Participants","GLAXOSMITHKLINE: A Phase 1, Randomized, Double-Blind, Single Ascending Dose Study to Determine the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX Administered Subcutaneously in Healthy Participants"
 ,,
2020,"POLPHARMA PB006-01-03: A Phase 1, Single Dose, Randomized, Double-Blind Parallel Group Study to Compare the Pharmacokinetics and Pharmacodynamics of XXXX with XXXX in Healthy Subjects.","POLPHARMA: A Phase 1, Single Dose, Randomized, Double-Blind Parallel Group Study to Compare the Pharmacokinetics and Pharmacodynamics of XXXX with XXXX in Healthy Subjects."
2019,"BMS IM026002: A phase I ,A Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunologic Effects of XXXXX, and a Relative Bioavailability Study in Healthy Participants  ","BMS: A phase I ,A Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunologic Effects of XXXXX, and a Relative Bioavailability Study in Healthy Participants  "
Cardiovascular,,
2023,"BRISTOL-MYERS SQUIBB CV028-1012: A Phase 1, Open-label, Randomized, Single-dose, 3-Period, 3-Sequence Crossover Study to Assess the Relative Bioavailability of the Intended Commercial Formulation Versus the Precious MyoKardia Formulation of XXXX and to Assess the Effect of Food on the Pharmacokinetics of the Intended Commercial Formulation in Healthy Adult Participants  ","BRISTOL-MYERS SQUIBB: A Phase 1, Open-label, Randomized, Single-dose, 3-Period, 3-Sequence Crossover Study to Assess the Relative Bioavailability of the Intended Commercial Formulation Versus the Precious MyoKardia Formulation of XXXX and to Assess the Effect of Food on the Pharmacokinetics of the Intended Commercial Formulation in Healthy Adult Participants  "
2023,"BRISTOL-MYERS SQUIBB CV027-1052: An Open-label, Randomized, Single-dose, Three-way Crossover Study to Establish Bioequivalence of 5 mg XXXX Capsule 1 and 5 × 1 mg XXXX Capsule 2 to 5 mg XXXX Capsule 2 in Healthy Participants ","BRISTOL-MYERS SQUIBB: An Open-label, Randomized, Single-dose, Three-way Crossover Study to Establish Bioequivalence of 5 mg XXXX Capsule 1 and 5 × 1 mg XXXX Capsule 2 to 5 mg XXXX Capsule 2 in Healthy Participants "
2023,"PFIZER C5001001: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of XXXX in Healthy Adult Participants and Repeat Doses in Participants with Pulmonary Arterial Hypertension  ","PFIZER: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of XXXX in Healthy Adult Participants and Repeat Doses in Participants with Pulmonary Arterial Hypertension  "
2021,"AMGEN, INC. 20180224: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG XXXX in Subjects with Obesity. ","AMGEN, INC.: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG XXXX in Subjects with Obesity. "
2021,"BRISTOL-MYERS SQUIBB RESEARCH AND DEVELOPMENT MB130101: An Open-label, Randomized, Two-Period Cross-over Study to Investigate the Relative Bioavailability of XXXX in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration with Auto-injector Versus Pre-filled Syringe. ","BRISTOL-MYERS SQUIBB RESEARCH AND DEVELOPMENT: An Open-label, Randomized, Two-Period Cross-over Study to Investigate the Relative Bioavailability of XXXX in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration with Auto-injector Versus Pre-filled Syringe. "
Dermatology,,
2024,"ELI LILLY AND COMPANY J4L-MC-KMAA: a Phase I, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Single-Ascending Dose Study of XXXX in Healthy Participants, a Multiple-Ascending Dose Study of XXXX in Patients with Atopic Dermatitis, and an Open-Label Multiple-Dose Evaluation of the Safety and Tolerability of Prednisone in Health Participants.","ELI LILLY AND COMPANY: a Phase I, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Single-Ascending Dose Study of XXXX in Healthy Participants, a Multiple-Ascending Dose Study of XXXX in Patients with Atopic Dermatitis, and an Open-Label Multiple-Dose Evaluation of the Safety and Tolerability of Prednisone in Health Participants."
2024,"PFIZER C4991001: A Phase 1, First in Human, Randomized, Double-Blind, Sponsor open, Placebo-Controlled, Single- and Multiple Dose Escalation, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pf-07832837 in Healthy Participants and Participants with Moderate to Severe Atopic Dermatitis","PFIZER: A Phase 1, First in Human, Randomized, Double-Blind, Sponsor open, Placebo-Controlled, Single- and Multiple Dose Escalation, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of in Healthy Participants and Participants with Moderate to Severe Atopic Dermatitis"
2023,ABBIVE M24-696: A Phase 1 Pharmacokinetic Comparability Study in Healthy Subjects to Evaluate the Relative Bioavailability of XXXX in Vials Manufactured by Two Different Processes. ,ABBIVE: A Phase 1 Pharmacokinetic Comparability Study in Healthy Subjects to Evaluate the Relative Bioavailability of XXXX in Vials Manufactured by Two Different Processes. 
2020,"PFIZER C4461001: A Phase 1 First In Human, Randomized, Double Blind, Sponsor Open, Placebo-Controlled, Single- and Multiple Dose Escalation, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX in Healthy Participants and Participants with Atopic Dermatitis.","PFIZER: A Phase 1 First In Human, Randomized, Double Blind, Sponsor Open, Placebo-Controlled, Single- and Multiple Dose Escalation, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX in Healthy Participants and Participants with Atopic Dermatitis."
2019," AbbVie M17-238: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of XXXXX in Healthy Volunteers and in Subjects with Chronic Plaque Psoriasis. "," AbbVie: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of XXXXX in Healthy Volunteers and in Subjects with Chronic Plaque Psoriasis. "
2019,"AbbVie M15-999: A Phase 2-4 Study, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of the XXXXX Using a New Formulation for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis.","AbbVie: A Phase 2-4 Study, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of the XXXXX Using a New Formulation for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis."
 ,,
Endocrinology/Metabolic,,
2025,"AMGEN INC. 20230259 (777790): A Phase 1, Open-Label, Randomized, Parallel-group Study to Assess the Relative Bioavailability of Maridebart Cafraglutide (AMG 133) As Two Subcutaneous Presentations in Participants Living With Overweight or Obesity","AMGEN INC.: A Phase 1, Open-Label, Randomized, Parallel-group Study to Assess the Relative Bioavailability of XXX (XXX) As Two Subcutaneous Presentations in Participants Living With Overweight or Obesity"
2025,"AMGEN 20210268: A Phase 1, Open-label, Randomized, Parallel-group Study to Assess the Relative Bioavailability of Maridebart Cafraglutide (AMG 133) as Two Subcutaneous Presentations in Participants Living with Overweight or Obesity","AMGEN: A Phase 1, Open-label, Randomized, Parallel-group Study to Assess the Relative Bioavailability of Maridebart Cafraglutide (XXX) as Two Subcutaneous Presentations in Participants Living with Overweight or Obesity"
2025,"KAILERA K7535-1709: A Phase 1, Open-Label, Randomized, Crossover Study to Evaluate the Effect of a Low Fat Meal and Evening Dosing on the Pharmacokinetics and Tolerability of KAI-7535 in Healthy Participants Living with Obesity or Overweight","KAILERA: A Phase 1, Open-Label, Randomized, Crossover Study to Evaluate the Effect of a Low Fat Meal and Evening Dosing on the Pharmacokinetics and Tolerability of XXX in Healthy Participants Living with Obesity or Overweight"
2025,"ELI LILLYANDCOMPANY J3R-MC-YDAE: A Phase 1, Open-Label, Single and Multiple Dose Study to Investigate the Safety, Tolerability, and Relative Bioavailability of Single and Multiple Weekly Subcutaneous Doses of XXXX, and Single and Multiple Weekly Subcutaneous Doses of XXXX with XXXX in Participants with Overweight or Obesity","ELI LILLYANDCOMPANY: A Phase 1, Open-Label, Single and Multiple Dose Study to Investigate the Safety, Tolerability, and Relative Bioavailability of Single and Multiple Weekly Subcutaneous Doses of XXXX, and Single and Multiple Weekly Subcutaneous Doses of XXXX with XXXX in Participants with Overweight or Obesity"
2025,"PFIZER C5541009: A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Pharmacokinetic Interactions Between XXXX and XXX in Otherwise Healthy Adult Participants with Overweight or Obesity       ","PFIZER: A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Pharmacokinetic Interactions Between XXXX and XXX in Otherwise Healthy Adult Participants with Overweight or Obesity       "
2024,"AMGEN 20240195: A Phase 1, Randomized, Double-blind, Multiple-dose Study to Evaluate the Pharmacokinetics of AMG 133 Administered Subcutaneously in Subjects with Overweight or Obesity","AMGEN: A Phase 1, Randomized, Double-blind, Multiple-dose Study to Evaluate the Pharmacokinetics of XXX XXX Administered Subcutaneously in Subjects with Overweight or Obesity"
2024,"AMGEN 20230022:  A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 513 in Participants with Obesity","AMGEN:  A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXX in Participants with Obesity"
2024,"AMGEN 20210205: A Phase 1, Randomized, Open-label, Single-dose, Parallel Group Study to Assess the Relative Bioavailability of AMG 133 Administered Using One of Three Drug Products in Participants Living with Overweight or Obesity","AMGEN: A Phase 1, Randomized, Open-label, Single-dose, Parallel Group Study to Assess the Relative Bioavailability of XXX Administered Using One of Three Drug Products in Participants Living with Overweight or Obesity"
2024,ELI LILLY J2A-MC-GZPI: A Multiple-Dose Study to Investigate the Bioequivalence of Orforglipron (LY3502970) Capsules and Orforglipron Tablets in Participants with Obesity or Overweight who are Otherwise Healthy,ELI LILLY: A Multiple-Dose Study to Investigate the Bioequivalence of Orforglipron (LY3502970) Capsules and Orforglipron Tablets in Participants with Obesity or Overweight who are Otherwise Healthy
2024,"ELI LILLY AND COMPANY J4P-MC-IYAA: A Single- and Multiple-Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Participants with Type 2 Diabetes Mellitus","ELI LILLY AND COMPANY: A Single- and Multiple-Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Participants with Type 2 Diabetes Mellitus"
2024,"PFIZER C4001002: A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled Study to assess the Safety, Tolerability, and Pharmacokinetics of Multiple Escalating Oral Doses of XXXX in Adult Participants with Type 2 Diabetes Mellitus","PFIZER: A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled Study to assess the Safety, Tolerability, and Pharmacokinetics of Multiple Escalating Oral Doses of XXXX in Adult Participants with Type 2 Diabetes Mellitus"
2023,"GASHERBRUM GSBR-1290-02: A Phase 1b/2a, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of XXXX in Adult Overweight or Obese Healthy Subjects and in Subjects with Type 2 Diabetes Mellitus on Metformin ","GASHERBRUM: A Phase 1b/2a, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of XXXX in Adult Overweight or Obese Healthy Subjects and in Subjects with Type 2 Diabetes Mellitus on Metformin "
2023,"REGENERON R1033-OB-2288: A randomized, double-blind study of the efficacy and Safety of Trevogrumab, with or without Garetosmab, in Addition to Semaglutide in patients with obesity   ","REGENERON: A randomized, double-blind study of the efficacy and Safety of XXX, with or without XXX, in Addition to Semaglutide in patients with obesity   "
2022,"ECCOGENE EC0004: A Randomized, Double-Blind, Placebo-Controlled, Single and Repeated Dose Escalation, First-Time-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX in Healthy Participants and in Patients with Type 2 Diabetes Mellitus","ECCOGENE: A Randomized, Double-Blind, Placebo-Controlled, Single and Repeated Dose Escalation, First-Time-In-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX in Healthy Participants and in Patients with Type 2 Diabetes Mellitus"
2022,"ELI LILLY & CO J1R-MC-GZFB: A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX Alone and in Combination with XXXX in Patients with Type 2 Diabetes","ELI LILLY & CO: A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX Alone and in Combination with XXXX in Patients with Type 2 Diabetes"
2020,"AMGEN, INC. 20180048: A Phase 1, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX in Subjects with Obesity. ","AMGEN, INC.: A Phase 1, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX in Subjects with Obesity. "
 ,,
2020,"ELI LILLY & CO J1I-MC-GZHC: A Phase 1, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Subcutaneous Doses of XXXX in Patients with Type 2 Diabetes Mellitus.","ELI LILLY & CO: A Phase 1, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Subcutaneous Doses of XXXX in Patients with Type 2 Diabetes Mellitus."
 ,,
2020,"ELI LILLY & CO J1I-MC-GZBB: A Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX in Patients with Type 2 Diabetes Mellitus","ELI LILLY & CO: A Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX in Patients with Type 2 Diabetes Mellitus"
2020,"PFIZER C3421007: Phase 1, Open-Label, Fixed Sequence Study to Evaluate the Effect of Two Dose Levels of XXXX on the Pharmacokinetics of Single Oral Doses of XXXX and XXXX, Administered Separately in Adult Participants with Obesity. ","PFIZER: Phase 1, Open-Label, Fixed Sequence Study to Evaluate the Effect of Two Dose Levels of XXXX on the Pharmacokinetics of Single Oral Doses of XXXX and XXXX, Administered Separately in Adult Participants with Obesity. "
2020,"PFIZER C3991002: A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Escalating Oral Doses of XXXX in Adult Participants with Type 2 Diabetes Mellitus.","PFIZER: A Phase 1, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Escalating Oral Doses of XXXX in Adult Participants with Type 2 Diabetes Mellitus."
2019,"Applied AT-007-1001: A Phase 1-2, Dose-Escalating, 4-Part Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of XXXXX in Healthy Adult Subjects and Adult Subjects with Classic Galactosemia (CG)  ","Applied: A Phase 1-2, Dose-Escalating, 4-Part Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of XXXXX in Healthy Adult Subjects and Adult Subjects with Classic Galactosemia (CG)  "
2019,"Novo Nordisk NN1436-4465: A Trial Comparing XXXX (XXX) Versus Insulin Glargine XXX, Both in Combination with Metformin, With or Without XXX Inhibitors and With or Without XXX Inhibitors, In Insulin-Naïve Subjects with Type 2 Diabetes Mellitus. ","Novo Nordisk: A Trial Comparing XXXX (XXX) Versus Insulin Glargine XXX, Both in Combination with Metformin, With or Without XXX Inhibitors and With or Without XXX Inhibitors, In Insulin-Naïve Subjects with Type 2 Diabetes Mellitus. "
2019,Novo Nordisk NN9838-4433: Investigation of safety and efficacy of XXXXX for weight management –a dose finding trial   ,Novo Nordisk: Investigation of safety and efficacy of XXXXX for weight management –a dose finding trial   
2019,"PegBio PB119202: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Cohort Study to Evaluate the Efficacy and Safety of Twelve Once-Weekly Subcutaneous Doses of XXXXX to Patients with Type 2 Diabetes Metformin Monotherapy.","PegBio: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Cohort Study to Evaluate the Efficacy and Safety of Twelve Once-Weekly Subcutaneous Doses of XXXXX to Patients with Type 2 Diabetes Metformin Monotherapy."
2019,"Selecta Biosciences SEL-212/201: An Open Label Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of XXX Followed by Open Label Administration of XXXXX in Subjects with Symptomatic Gout and Elevated Blood Uric Acid (XXX) ","Selecta Biosciences : An Open Label Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of XXX Followed by Open Label Administration of XXXXX in Subjects with Symptomatic Gout and Elevated Blood Uric Acid (XXX) "
2019,"Shanton XXXX: A Multicenter, Randomized, Double-blind, Placebo controlled, Dose escalation study to evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of XXXXX in Gout Patients with Hyperuricemia. ","Shanton: A Multicenter, Randomized, Double-blind, Placebo controlled, Dose escalation study to evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of XXXXX in Gout Patients with Hyperuricemia. "
2019,"Shanton SAP001-1-002: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pgarmacokinetics, and Pharmacodynamics of XXXXX in Gout Patients with Hyperuricemia.","Shanton: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pgarmacokinetics, and Pharmacodynamics of XXXXX in Gout Patients with Hyperuricemia."
 ,,
Ethnic Bridging,,
2025,"IMMUNOVANT SCIENCES GmbH IMVT-1401-1005: A Phase 1, Open-Label Study to Access Pharmacodynamics, Safety and Tolerability of XXXX Following a Single Subcutaneous Dose in Healthy Participants of Japanese Origin.","IMMUNOVANT SCIENCES GmbH: A Phase 1, Open-Label Study to Access Pharmacodynamics, Safety and Tolerability of XXXX Following a Single Subcutaneous Dose in Healthy Participants of Japanese Origin."
2024,"BRISTOLMYERSQUIBB IM045-1009: A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to evaluate the Safety, Tolerability, Pharmacodynamics of Orally Administered XXXX in Health Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity","BRISTOLMYERSQUIBB: A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to evaluate the Safety, Tolerability, Pharmacodynamics of Orally Administered XXXX in Health Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity"
2024,ELI LILLY AND COMPANY J4U-MC-KTAA: Single-and Multiple-Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of XXXX Following Oral Dosing in Healthy Participants,ELI LILLY AND COMPANY: Single-and Multiple-Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of XXXX Following Oral Dosing in Healthy Participants
2023,"ABBVIE M24-227: A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of XXXX in Healthy Adult Japanese and Han Chinese Subjects","ABBVIE: A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of XXXX in Healthy Adult Japanese and Han Chinese Subjects"
2023,"ABBVIE M23-512: An Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of XXXX in Healthy Adult Japanese and Han Chinese Subjects","ABBVIE: An Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of XXXX in Healthy Adult Japanese and Han Chinese Subjects"
2023,"BRISTOL-MYERS SQUIBB CV028-1001: A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Japanese and Caucasian Participants     ","BRISTOL-MYERS SQUIBB: A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Japanese and Caucasian Participants     "
2023,"ELI LILLY & CO J4F-MC-CYAA: A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, and Pharmacokinetics with Single Intravenous Ascending Doses and Single and Multiple Subcutaneous Doses of XXXX in Healthy Participants, Including First-Generation Japanese Participants ","ELI LILLY & CO: A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, and Pharmacokinetics with Single Intravenous Ascending Doses and Single and Multiple Subcutaneous Doses of XXXX in Healthy Participants, Including First-Generation Japanese Participants "
2023,"GASHERBRUM GSBR-1290-03: A Phase 1, Randomized, Double-blind, Placebo-controlled Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of XXXX in Japanese and Non-Japanese Healthy Volunteers     ","GASHERBRUM: A Phase 1, Randomized, Double-blind, Placebo-controlled Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of XXXX in Japanese and Non-Japanese Healthy Volunteers     "
2023,GILEAD GS-US-611-6586: A Phase 1 Single-Dose Study to Evaluate the Pharmacokinetics and Tolerability of XXXX (XXXX) in Healthy Japanese and White Participants    ,GILEAD: A Phase 1 Single-Dose Study to Evaluate the Pharmacokinetics and Tolerability of XXXX (XXXX) in Healthy Japanese and White Participants    
2023,"IDORSIA ID-078-127: A Single-Center, Open-Label, Randomized, Crossover Phase 1 Trial to Investigate Bioequivalence Between 5 x 10 mg tablets and 2 x 25 mg tablets of XXXX in Healthy Male and Female Japanese Participants  ","IDORSIA: A Single-Center, Open-Label, Randomized, Crossover Phase 1 Trial to Investigate Bioequivalence Between 5 x 10 mg tablets and 2 x 25 mg tablets of XXXX in Healthy Male and Female Japanese Participants  "
2023,"VENTYX VTX958-106: A Phase 1, Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of XXXX Following an Oral Administration in Healthy Japanese and Caucasian Subjects ","VENTYX: A Phase 1, Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of XXXX Following an Oral Administration in Healthy Japanese and Caucasian Subjects "
2022,"ABBVIE M22-720: This is a Phase 1, double-blind, sequential, placebo-controlled, single center, randomized study in which healthy Japanese subjects will receive a single XXXX dose or placebo. Healthy Han Chinese subjects will also receive a single XXXX dose, but no Han Chinese subjects will receive placebo, and there will be no randomization of Han Chinese subjects. A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of XXXX in Healthy Adult, Japanese, and Han Chinese Subjects","ABBVIE: This is a Phase 1, double-blind, sequential, placebo-controlled, single center, randomized study in which healthy Japanese subjects will receive a single XXXX dose or placebo. Healthy Han Chinese subjects will also receive a single XXXX dose, but no Han Chinese subjects will receive placebo, and there will be no randomization of Han Chinese subjects. A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of XXXX in Healthy Adult, Japanese, and Han Chinese Subjects"
2022,"BIOGEN 283HV101: An Open-Label, Parallel-Group, Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of XXXX In Healthy Adult Japanese, Chinese, And Caucasian Participants","BIOGEN: An Open-Label, Parallel-Group, Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of XXXX In Healthy Adult Japanese, Chinese, And Caucasian Participants"
2022,"BIOGEN 221HV104: A Randomized, Open-Label, Parallel-Arm Study to Assess the Pharmacokinetic Comparability of 2 Fixed Subcutaneous Doses of XXXX (XXXX) With a Single, Weight-Based Intravenous Dose in Healthy Volunteers  ","BIOGEN: A Randomized, Open-Label, Parallel-Arm Study to Assess the Pharmacokinetic Comparability of 2 Fixed Subcutaneous Doses of XXXX (XXXX) With a Single, Weight-Based Intravenous Dose in Healthy Volunteers  "
2022,"BRISTOL-MYERS SQUIBB IM032-042: A Double-blind, Placebo-controlled, Randomized, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Participants of Japanese Descent","BRISTOL-MYERS SQUIBB: A Double-blind, Placebo-controlled, Randomized, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Participants of Japanese Descent"
2022,"BRISTOL-MYERS SQUIBB CV029-014: A Phase 1 Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of XXXX in Healthy Adult Japanese Participants ","BRISTOL-MYERS SQUIBB: A Phase 1 Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of XXXX in Healthy Adult Japanese Participants "
2022,"BRISTOL-MYERS SQUIBB CN007-001_EVT-21683: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Participants including Healthy Participants of Japanese Ethnicity and an Open-label Assessment of Food Effects on the Relative Bioavailability of XXXX / XXXX  ","BRISTOL-MYERS SQUIBB: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Participants including Healthy Participants of Japanese Ethnicity and an Open-label Assessment of Food Effects on the Relative Bioavailability of XXXX / XXXX  "
2022,"CINCOR CIN-107-126: A Phase 1 Single and Multiple Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of XXXX in Healthy Japanese and Caucasian Subjects  ","CINCOR: A Phase 1 Single and Multiple Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of XXXX in Healthy Japanese and Caucasian Subjects  "
2022,"GILEAD SCIENCES GS-US-457-6026: A Single- and Multiple-Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Japanese Participants  ","GILEAD SCIENCES: A Single- and Multiple-Dose Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Japanese Participants  "
2022,"INTRA-CELLULAR ITI-007-034: An Open-Label, Ascending Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of XXXX in Healthy Japanese and Healthy Caucasian Subjects  ","INTRA-CELLULAR: An Open-Label, Ascending Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of XXXX in Healthy Japanese and Healthy Caucasian Subjects  "
2022,"SUMITOVANT KSP-1007-001: A Phase I Randomized, Double-Blind, Multi-Part, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Dose of XXXX Alone and Co-administered with Meropenem in Healthy Subjects   ","SUMITOVANT: A Phase I Randomized, Double-Blind, Multi-Part, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Dose of XXXX Alone and Co-administered with Meropenem in Healthy Subjects   "
2021,"BIOGEN 263HV108: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Japanese and Non-Japanese Participants.  ","BIOGEN: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Japanese and Non-Japanese Participants.  "
2021,"ELI LILLY & COMPANY J3D-MC-FNAA: A Phase 1, Randomized, Participant-and Investigator-Blind, Placebo-Controlled, Single-and Multiple-Ascending Dose, Drug-Drug Interaction and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Non-Japanese and Japanese Participants.","ELI LILLY & COMPANY: A Phase 1, Randomized, Participant-and Investigator-Blind, Placebo-Controlled, Single-and Multiple-Ascending Dose, Drug-Drug Interaction and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXXX in Healthy Non-Japanese and Japanese Participants."
2021,"GLAXOSMITHKLINE 217653: A Phase I, Single-Blind, Randomized, Single-Dose Clinical Pharmacology Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of XXXX Vs Placebo By Intravenous Or Intramuscular Administration In Healthy Japanese And Caucasian Participants.","GLAXOSMITHKLINE: A Phase I, Single-Blind, Randomized, Single-Dose Clinical Pharmacology Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of XXXX Vs Placebo By Intravenous Or Intramuscular Administration In Healthy Japanese And Caucasian Participants."
2021,"QED THERAPEUTICS QBGJ398-114: A Phase 1, An Open-Label, Multiple Dose, Ethnic Sensitivity Study of XXXX (XXXX) XXXX mg in Japanese vs. Caucasian Healthy Subjects.","QED THERAPEUTICS: A Phase 1, An Open-Label, Multiple Dose, Ethnic Sensitivity Study of XXXX (XXXX) XXXX mg in Japanese vs. Caucasian Healthy Subjects."
2021,"TEVA TV48574-PK-10180: An Open-Label, Randomized, Phase 1 Subcutaneous Single-Dose Study to Assess the Pharmacokinetics, Safety, Immunogenicity, and Tolerability of XXXX (Doses up to XXXX mg) in Healthy Adult Japanese and Caucasian Subjects. ","TEVA: An Open-Label, Randomized, Phase 1 Subcutaneous Single-Dose Study to Assess the Pharmacokinetics, Safety, Immunogenicity, and Tolerability of XXXX (Doses up to XXXX mg) in Healthy Adult Japanese and Caucasian Subjects. "
2021,"UCB BIOPHARMA UP0101: A Placebo-Controlled, Double-Blind, Randomized Study to Assess the Safety, Tolerability, and Pharmacokinetics (PK) of XXXX XXXX in Healthy Japanese, Chinese, and Caucasian Participants  ","UCB BIOPHARMA: A Placebo-Controlled, Double-Blind, Randomized Study to Assess the Safety, Tolerability, and Pharmacokinetics (PK) of XXXX XXXX in Healthy Japanese, Chinese, and Caucasian Participants  "
2020,"BIOGEN 253HV101: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ascending, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX XXXX (XXXX) in Healthy Male Japanese and Caucasian Study Participants.","BIOGEN: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ascending, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX XXXX (XXXX) in Healthy Male Japanese and Caucasian Study Participants."
 ,,
2020,"CELLTRION CT-P16 1.2: A Phase 1, Randomized, Double-blind, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of XXXX and EU-Approved XXXX in Healthy Japanese Male Subjects  ","CELLTRION: A Phase 1, Randomized, Double-blind, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of XXXX and EU-Approved XXXX in Healthy Japanese Male Subjects  "
 ,,
2020,"CSL BEHRING CSL312-1003: A 2-Part, Phase 1, Single Center, Open-label, Single Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Subcutaneous and Intravenous XXXX in Healthy Adult Japanese and Caucasian Subjects. ","CSL BEHRING: A 2-Part, Phase 1, Single Center, Open-label, Single Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Subcutaneous and Intravenous XXXX in Healthy Adult Japanese and Caucasian Subjects. "
2019,"Amgen 20180222: A Phase 1, Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of XXXXX in Japanese Subjects with Elevated Plasma Lipoprotein(a). .","Amgen: A Phase 1, Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of XXXXX in Japanese Subjects with Elevated Plasma Lipoprotein(a). ."
2019,"AnaptysBio ANB019-005: A Phase 1, Single-Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of XXXXX in Healthy Japanese and Caucasian Subjects.","AnaptysBio: A Phase 1, Single-Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of XXXXX in Healthy Japanese and Caucasian Subjects."
2019,"Celgene CC-93538-CP-001: A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of XXXXX in Healthy Japanese and Caucasian Adult Subjects.","Celgene: A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of XXXXX in Healthy Japanese and Caucasian Adult Subjects."
2019,"Esperion ETC-1002-063: A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending and Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of XXXXX Acid in Healthy Japanese and Additional East Asian Ethnicity Cohorts.","Esperion: A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending and Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of XXXXX Acid in Healthy Japanese and Additional East Asian Ethnicity Cohorts."
2019,"Idorsia ID-064-104: A Phase 1, Single-Center, Double-Blind, Placebo-Controlled, Randomized Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics after Single-Dose Administration of 4mg XXXXX in Healthy Japanese and Caucasian Subjects.","Idorsia: A Phase 1, Single-Center, Double-Blind, Placebo-Controlled, Randomized Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics after Single-Dose Administration of 4mg XXXXX in Healthy Japanese and Caucasian Subjects."
2019,"Pfizer C3651002: A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate The Safety, Tolerability and Pharmacokinetics of Single-Dose Subcutaneous Administration of XXXXX to Healthy Adult Japanese Participants.","Pfizer: A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate The Safety, Tolerability and Pharmacokinetics of Single-Dose Subcutaneous Administration of XXXXX to Healthy Adult Japanese Participants."
Hepatology,,
2023,"PFIZER C5091014: A Phase 1, Open-label, Single-dose, Parallel Group Study to Assess Pharmacokinetics, Safety and Tolerability of XXXX in Adult Participants with Varying Degrees of Hepatic Impairment Relative to Participants Without Hepatic Impairment  ","PFIZER: A Phase 1, Open-label, Single-dose, Parallel Group Study to Assess Pharmacokinetics, Safety and Tolerability of XXXX in Adult Participants with Varying Degrees of Hepatic Impairment Relative to Participants Without Hepatic Impairment  "
Gastroenterology,,
2024,"ECCOGENE EC0006: An Open-Label, Randomized, Single Dose, Crossover Clinical Study to Assess the Relative Bioavailability of Current Tablet Formulation (F1) Compared to New Table Formulation (F2) of XXXX and Food Effects on F1 and F2 XXXX in Healthy Participants","ECCOGENE: An Open-Label, Randomized, Single Dose, Crossover Clinical Study to Assess the Relative Bioavailability of Current Tablet Formulation (F1) Compared to New Table Formulation (F2) of XXXX and Food Effects on F1 and F2 XXXX in Healthy Participants"
2023,"PFIZER C5281001/KAN-101-02: A Phase 1B Open-Label/Phase 2 Double-Blind Placebo-Controlled Study for Pharmacodynamic Activity, Pharmacokinetics, Safety and Tolerability of XXXX in Patients with Celiac Disease","PFIZER: A Phase 1B Open-Label/Phase 2 Double-Blind Placebo-Controlled Study for Pharmacodynamic Activity, Pharmacokinetics, Safety and Tolerability of XXXX in Patients with Celiac Disease"
2020,KANYOS: KAN-101-01 A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of XXXX in Patients with Celiac Disease.  ,KANYOS: A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of XXXX in Patients with Celiac Disease.  
2020,"PVP BIOLOGICS PvP-102-01: A Phase 1, Four-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Gluten Degradation Activity of XXXX, XXXX, and XXXX in Healthy Adult Volunteers and to Assess the Safety, Tolerability, and Pharmacokinetics of XXXX and XXXX in Adults with Celiac Disease","PVP BIOLOGICS: A Phase 1, Four-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Gluten Degradation Activity of XXXX, XXXX, and XXXX in Healthy Adult Volunteers and to Assess the Safety, Tolerability, and Pharmacokinetics of XXXX and XXXX in Adults with Celiac Disease"
2019,"Gossamer GB004-1902: A Phase 1a, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Tablet Formulations of XXXXX in Healthy Male and Female Volunteers.","Gossamer: A Phase 1a, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Tablet Formulations of XXXXX in Healthy Male and Female Volunteers."
2019,"Phathom EE-301: A Phase 3, Randomized, Double-Blind, Two Phase, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 20 mg Compared to Lansoprazole 30 mg for Healing in Patients with Erosive Esophagitis and to Evaluate the Efficacy and Safety of Vonoprazan (10 mg and 20 mg) Compared to Lansoprazole 15 mg for the Maintenance of Healing in Patients with Healed Erosive Esophagitis. ","Phathom: A Phase 3, Randomized, Double-Blind, Two Phase, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan 20 mg Compared to Lansoprazole 30 mg for Healing in Patients with Erosive Esophagitis and to Evaluate the Efficacy and Safety of Vonoprazan (10 mg and 20 mg) Compared to Lansoprazole 15 mg for the Maintenance of Healing in Patients with Healed Erosive Esophagitis. "
 ,,
2019,"Phathom HP-301: A Phase 3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy with Oral Vonoprazan 20 mg or Double-Blind Triple Therapy with Oral Vonoprazan 20 mg Compared to Double-Blind Triple Therapy with Oral Lansoprazole 30 mg Daily in Patients with Helicobacter Pylori Infection.","Phathom: A Phase 3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy with Oral Vonoprazan 20 mg or Double-Blind Triple Therapy with Oral Vonoprazan 20 mg Compared to Double-Blind Triple Therapy with Oral Lansoprazole 30 mg Daily in Patients with Helicobacter Pylori Infection."
 ,,
2019,"PVP XXXX: A Phase 1, Two-Part Study to Assess the Safety and Pharmacokinetics of XXX and XXX in Healthy Adult volunteers and Adults with Celiac Disease and to Asses the Gluten Degradation Activity of XXX and XXX in Healthy Adult Volunteers (XXX) ","PVP: A Phase 1, Two-Part Study to Assess the Safety and Pharmacokinetics of XXX and XXX in Healthy Adult volunteers and Adults with Celiac Disease and to Asses the Gluten Degradation Activity of XXX and XXX in Healthy Adult Volunteers (XXX) "
 ,,
Immunology,,
2024,"GILEAD GS-US-668-6703: A Phase 1a Study to Evaluate Safety, Tolerability, and Pharmacokinetics of GS-3242 for Injection in Healthy Participants","GILEAD: A Phase 1a Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XXX for Injection in Healthy Participants"
2023,"BIOGEN 271HV101: A Phase 1, Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX in Healthy Adult Participants","BIOGEN : A Phase 1, Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX in Healthy Adult Participants"
2023,"BRISTOL-MYERS SQUIBB IM054-003: A Phase 1 Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single, Ascending Doses of XXXX in Healthy Adult Participants  (Immunomodulator)","BRISTOL-MYERS SQUIBB: A Phase 1 Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single, Ascending Doses of XXXX in Healthy Adult Participants  (Immunomodulator)"
2023,"BIOGEN 272HV112: A Phase 1, randomized, Double-Blind, Crossover Study to Evaluate the Bioequivalence of XXXX (XXXX, XXXX) Manufactured at Biogen Oral Solid Dose (OSD) in Healthy Adult Participants  ","BIOGEN: A Phase 1, randomized, Double-Blind, Crossover Study to Evaluate the Bioequivalence of XXXX (XXXX, XXXX) Manufactured at Biogen Oral Solid Dose (OSD) in Healthy Adult Participants  "
Neurology,,
2024,"ADEL, INC. AND OSCOTEC INC. ADEL_OSCO_Y01-P101: First in Human, Phase Ia/Ib Study for Safety, Tolerability, Pharmacokinetics, and Clinical Activity Evaluation of XXXX in Healthy Participants and in Participants with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer","ADEL, INC. AND OSCOTEC INC.: First in Human, Phase Ia/Ib Study for Safety, Tolerability, Pharmacokinetics, and Clinical Activity Evaluation of XXXX in Healthy Participants and in Participants with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer"
2023,"BRISTOL-MYERS SQUIBB CN007-1001: A Phase 1, Open-label, Randomized, Parallel-group, Single dose Study to Assess the Relative Bioavailability of a New XXXX Immediate-release Tablet Formulation Compared to a Reference Enteric Capsule (Delayed-release) Formulation, and to Assess the Effect of Food on the Pharmacokinetics of Immediate-release Tablet Formulation in Healthy Adult Participants ","BRISTOL-MYERS SQUIBB: A Phase 1, Open-label, Randomized, Parallel-group, Single dose Study to Assess the Relative Bioavailability of a New XXXX Immediate-release Tablet Formulation Compared to a Reference Enteric Capsule (Delayed-release) Formulation, and to Assess the Effect of Food on the Pharmacokinetics of Immediate-release Tablet Formulation in Healthy Adult Participants "
2021,"EISAI, INC. BAN2401-A001-004: An Open-Label, Parallel-Group, Randomized Study to Evaluate the Absolute Bioavailability of a Single Dose Subcutaneous Administration of XXXX in Healthy Subjects.   ","EISAI, INC.: An Open-Label, Parallel-Group, Randomized Study to Evaluate the Absolute Bioavailability of a Single Dose Subcutaneous Administration of XXXX in Healthy Subjects.   "
Psychiatry,,
2023,ABBVIE M23-889: Generalized Anxiety Disorder (GAD): A First-in-Human Single Ascending Dose and Food Effect Study of XXXX in Healthy Adult Subjects  ,ABBVIE: Generalized Anxiety Disorder (GAD): A First-in-Human Single Ascending Dose and Food Effect Study of XXXX in Healthy Adult Subjects  
Vaccine,,
2025,"GILEAD GS-US-567-6968: Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-4321 in Healthy Participants and Participants with Chronic Hepatitis Delta","GILEAD: Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of XXX in Healthy Participants and Participants with Chronic Hepatitis Delta"
2025,"PFIZER C5211001: A Phase 1, Randomized, Double-Blind, Third-Party–Unblinded Study To Evaluate The Safety And Tolerability Of A Vaccine Against E Coli In Healthy Adults  ","PFIZER: A Phase 1, Randomized, Double-Blind, Third-Party–Unblinded Study To Evaluate The Safety And Tolerability Of A Vaccine Against E Coli In Healthy Adults  "
2025,"PFIZER C6271001: A Phase 1/2 Randomized, Double-Blinded Study to Evaluate the Safety, Tolerability, And Immunogenicity of Modified RNA Vaccine Candidates Against Influenza and Covid-19 In Healthy Individuals","PFIZER: A Phase 1/2 Randomized, Double-Blinded Study to Evaluate the Safety, Tolerability, And Immunogenicity of Modified RNA Vaccine Candidates Against Influenza and Covid-19 In Healthy Individuals"
2024,"ELI-LILLY&CO J4S-MC-KSAA: A Phase 1, randomized, placebo-controlled, investigator and participant blinded, single ascending dose and multiple ascending dose study to evaluate safety, tolerability, and pharmacokinetics of XXXX in healthy participants.","ELI-LILLY&CO: A Phase 1, randomized, placebo-controlled, investigator and participant blinded, single ascending dose and multiple ascending dose study to evaluate safety, tolerability, and pharmacokinetics of XXXX in healthy participants."
2024,"MERCK SHARP&DOHME V540BA002-03: Phase 1, Randomized, Double-Blind, Comparator-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of V540B in Healthy Adults.","MERCK SHARP&DOHME: Phase 1, Randomized, Double-Blind, Comparator-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of XXX in Healthy Adults."
2024,"PUBLIC HEALTH VACCINES PHV02-C-102: A Phase 1b Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Prime-Boost Regimen of Three Dose Levels of XXXX, a Nipah Virus Vaccine Candidate (rVSV-∆G-EBOV GP-NiVG) in Healthy Adults","PUBLIC HEALTH VACCINES: A Phase 1b Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Prime-Boost Regimen of Three Dose Levels of XXXX, a Nipah Virus Vaccine Candidate (XXX) in Healthy Adults"
2024,"PFIZER C4781013: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of XXXX Vaccines Against Influenza in Healthy Adults","PFIZER: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of XXXX Vaccines Against Influenza in Healthy Adults"
2023,"PFIZER C4771001: A Phase 1 Randomized and Phase 2 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Immunopersistence of a XXXX Vaccine Administered in a 2-Dose Regimen with Novel Adjuvants in Healthy Adults     ","PFIZER: A Phase 1 Randomized and Phase 2 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Immunopersistence of a XXXX Vaccine Administered in a 2-Dose Regimen with Novel Adjuvants in Healthy Adults     "
2021,"FLUGEN, INC. FLUGEN-H3N2-V005: A Phase 1b, Clinical Study to Investigate the Safety and Immunogenicity of the XXXX (A/Singapore/XXXX) XXXX Monovalent Influenza Vaccine in Adults Ages 50 To 85 Years Old.","FLUGEN, INC.: A Phase 1b, Clinical Study to Investigate the Safety and Immunogenicity of the XXXX (A/Singapore/XXXX) XXXX Monovalent Influenza Vaccine in Adults Ages 50 To 85 Years Old."
Women’s Health,,
2023,"PFIZER C3991040: A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Two Steady-State Dose Levels of XXXX on the Pharmacokinetics of Single-Dose XXXX, XXXX and an Oral Contraceptive, and the Effect of Steady-State XXXX on the Pharmacokinetics of Single-Dose XXXX, in Obese Adult Female Participants  ","PFIZER: A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Two Steady-State Dose Levels of XXXX on the Pharmacokinetics of Single-Dose XXXX, XXXX and an Oral Contraceptive, and the Effect of Steady-State XXXX on the Pharmacokinetics of Single-Dose XXXX, in Obese Adult Female Participants  "
2021,"GILEAD SCIENCES, INC. GS-US-556-5994: A Phase 1 Drug Interaction Study Evaluating the Effect of XXXX on the Pharmacokinetics of the Combined Hormonal Oral Contraceptive XXXX/XXXX in Healthy Female Subjects.","GILEAD SCIENCES, INC.: A Phase 1 Drug Interaction Study Evaluating the Effect of XXXX on the Pharmacokinetics of the Combined Hormonal Oral Contraceptive XXXX/XXXX in Healthy Female Subjects."
2021,"PFIZER C3421047: A Phase 1, Open-Label, Two-Part Study to Evaluate the Effect of Two Steady-State Dose Levels of XXXX On the Pharmacokinetics of Single Oral Doses of XXXX and XXXX In Healthy Adults and An Oral Contraceptive In Healthy Post-Menopausal Female.","PFIZER: A Phase 1, Open-Label, Two-Part Study to Evaluate the Effect of Two Steady-State Dose Levels of XXXX On the Pharmacokinetics of Single Oral Doses of XXXX and XXXX In Healthy Adults and An Oral Contraceptive In Healthy Post-Menopausal Female."
2020,KANYOS: KAN-101-01 A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of XXXX in Patients with Celiac Disease.  ,KANYOS: A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of XXXX in Patients with Celiac Disease.  
2020,"PVP BIOLOGICS PvP-102-01: A Phase 1, Four-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Gluten Degradation Activity of XXXX, XXXX, and XXXX in Healthy Adult Volunteers and to Assess the Safety, Tolerability, and Pharmacokinetics of XXXX and XXXX in Adults with Celiac Disease","PVP BIOLOGICS: A Phase 1, Four-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Gluten Degradation Activity of XXXX, XXXX, and XXXX in Healthy Adult Volunteers and to Assess the Safety, Tolerability, and Pharmacokinetics of XXXX and XXXX in Adults with Celiac Disease"
2020,"MILLENDO MLE-301-101: A Phase 1 Single Ascending Dose Study in Healthy Men, A Food-Effect Study in Postmenopausal Women, and A Multiple Ascending Dose Study in Postmenopausal Women with Vasomotor Symptoms (VMS) to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX.","MILLENDO: A Phase 1 Single Ascending Dose Study in Healthy Men, A Food-Effect Study in Postmenopausal Women, and A Multiple Ascending Dose Study in Postmenopausal Women with Vasomotor Symptoms (VMS) to Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX."
Other Indication,,
2024,"METSERA MET097-23-101: A Phase 1/2 Randomized Placebo-Controlled Double-Blind Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Doses of Met097 in Adult Participants with Obesity or Overweight but Otherwise Healthy","METSERA: A Phase 1/2 Randomized Placebo-Controlled Double-Blind Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Doses of XXX in Adult Participants with Obesity or Overweight but Otherwise Healthy"
2024,"PFIZER C5351008: A Phase 1, Open-Label, Randomized, Single-Dose, Parallel Design, Study to Evaluate Pharmacokinetic Comparability of Two XXXX Film-Coated Tablet Formulations Administered as 150 MG Under Fasted Conditions","PFIZER: A Phase 1, Open-Label, Randomized, Single-Dose, Parallel Design, Study to Evaluate Pharmacokinetic Comparability of Two XXXX Film-Coated Tablet Formulations Administered as 150 MG Under Fasted Conditions"
2023,"GILEAD GS-US-611-6469: A Phase 1 Study to Evaluate Transporter and Cytochrome P450 Enzyme (CYP)-Mediated Drug-Drug Interactions Between XXXX and XXXX, XXXX, and XXXX in Healthy Participants ","GILEAD: A Phase 1 Study to Evaluate Transporter and Cytochrome XXX Mediated Drug-Drug Interactions Between XXXX and XXXX, XXXX, and XXXX in Healthy Participants "
2023,"VISTERRA VIS954-101: A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose, First-in-Human, Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX in Healthy Male and Female Participants  ","VISTERRA: A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose, First-in-Human, Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX in Healthy Male and Female Participants  "
2022,"CSL BEHRING CSL312_1004: A Phase 1, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacokinetic Properties of XXXX Administered by Subcutaneous Autoinjector to Prefilled Syringe in Healthy Adult Subjects  ","CSL BEHRING: A Phase 1, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacokinetic Properties of XXXX Administered by Subcutaneous Autoinjector to Prefilled Syringe in Healthy Adult Subjects  "
2021,"ELI LILLY & COMPANY J2G-MC-JZJZ: An Open-Label, Randomized Study To Evaluate The Bioequivalence Of XXXX Tablet And Capsule Formulations","ELI LILLY & COMPANY: An Open-Label, Randomized Study To Evaluate The Bioequivalence Of XXXX Tablet And Capsule Formulations"
2019,"Durect C928-012: A Randomized, Open-Label, Phase 1b Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Signals of XXXXX in Patients with Non-Alcoholic Steatohepatitis (NASH).","Durect: A Randomized, Open-Label, Phase 1b Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Signals of XXXXX in Patients with Non-Alcoholic Steatohepatitis (NASH)."
2019,InterveXion M200C-1801 STAMPOUT: Study of Antibody for Methamphetamine Outpatient Therapy.,InterveXion: Study of Antibody for Methamphetamine Outpatient Therapy.
 ,,
PHASE II – IV,,
Dermatology,,
2023,"AMGEN 451 20210142: A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind, Study to Assess the Efficacy, Safety and Tolerability of XXXX (XXXX) Monotherapy in Adult Subjects with Moderate-to-severe Atopic Dermatitis (AD).","AMGEN: A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind, Study to Assess the Efficacy, Safety and Tolerability of XXXX (XXXX) Monotherapy in Adult Subjects with Moderate-to-severe Atopic Dermatitis (AD)."
Endocrinology/Metabolic,,
2025,"REGENERON: A Randomized, Double-Blind Study of the Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients with Obesity","REGENERON: A Randomized, Double-Blind Study of the Efficacy and Safety of XXX, With or Without Garetosmab, in Addition to Semaglutide in Patients with Obesity"
2025,"VERDIVA VRB-101-201: A Randomized, Double-Blind, Placebo-Controlled Phase 2B Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight with Weight-Related Comorbidities","VERDIVA: A Randomized, Double-Blind, Placebo-Controlled Phase 2B Study of Weekly Oral Ecnoglutide (XXX) in Participants Who Have Obesity or Overweight with Weight-Related Comorbidities"
2025,"PFIZER INC.(C5541010): A Phase 2A, Randomized, Double Blind, Sponsor-Open, Placebo-Controlled, Parallel Group, Dose-Ranging study of XXX-XX to assess Safety and Efficacy in Adult Participants with Obesity","PFIZER INC.: A Phase 2A, Randomized, Double Blind, Sponsor-Open, Placebo-Controlled, Parallel Group, Dose-Ranging study of XXX-XX to assess Safety and Efficacy in Adult Participants with Obesity"
2024,"METSERA MET233/097-25-201: A Phase 2B, Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Dose-Ranging Study To Investigate The Safety And Efficacy Of Weekly And Monthly Regimens Of Coad ministered MET233 And MET097 In Adult Participants With Overweight Or Obesity","METSERA: A Phase 2B, Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Dose-Ranging Study To Investigate The Safety And Efficacy Of Weekly And Monthly Regimens Of Coad ministered XXX And XXX In Adult Participants With Overweight Or Obesity"
2024,"AMGEN 20230143:   A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Subjects with Type 2 Diabetes Mellitus","AMGEN:   A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of XXX in Adult Subjects with Type 2 Diabetes Mellitus"
2024,"GASHERBRUM GSBR-1290-06: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of GSBR-1290 in Participants Living with Obesity (Body Mass Index ≥ 30 kg/m2) or Overweight (Body Mass Index ≥ 27 kg/m2) with at Least One Weight-related Comorbidity","GASHERBRUM: A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of XXX in Participants Living with Obesity (Body Mass Index ≥ 30 kg/m2) or Overweight (Body Mass Index ≥ 27 kg/m2) with at Least One Weight-related Comorbidity"
2023,"JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO ABP-671-301.: A Multicenter, Randomized, Double-blind, Controlled, Phase 2b/3 Study to Assess the Efficacy and Safety of XXX-XXX in Participants With Gout","JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO.: A Multicenter, Randomized, Double-blind, Controlled, Phase 2b/3 Study to Assess the Efficacy and Safety of XXX-XXX in Participants With Gout"
2022,"PFIZER C3991004: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Dose-Finding, Parallel Group Study to Assess Efficacy and Safety of XXXX, and Open-Label Oral XXXX, in Adults with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Metformin, and Separately XXXX Compared to Matching Placebo in Adults with Obesity but Without T2DM.","PFIZER: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Dose-Finding, Parallel Group Study to Assess Efficacy and Safety of XXXX, and Open-Label Oral XXXX, in Adults with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on Metformin, and Separately XXXX Compared to Matching Placebo in Adults with Obesity but Without T2DM."
2021,ELI LILLY & COMPANY J1I-MC-GZBF: A Phase 2 Study of Once-Weekly XXXX Compared with Placebo in Participants Who Have Obesity or Are Overweight with Weight-Related Comorbidities. ,ELI LILLY & COMPANY: A Phase 2 Study of Once-Weekly XXXX Compared with Placebo in Participants Who Have Obesity or Are Overweight with Weight-Related Comorbidities. 
2021,ELI LILLY & COMPANY J2A-MC-GZGE: A Phase 2 Study of Once-Daily XXXX Compared with Placebo and Once- Weekly XXXX in Participants with Type 2 Diabetes Mellitus   ,ELI LILLY & COMPANY: A Phase 2 Study of Once-Daily XXXX Compared with Placebo and Once- Weekly XXXX in Participants with Type 2 Diabetes Mellitus   
2021,ELI LILLY & COMPANY J2A-MC-GZGI: A Phase 2 Study of Once-Daily XXXX Compared with Placebo in Participants Who Have Obesity or Are Overweight with Weight-Related Comorbidities.,ELI LILLY & COMPANY: A Phase 2 Study of Once-Daily XXXX Compared with Placebo in Participants Who Have Obesity or Are Overweight with Weight-Related Comorbidities.
2021,"PFIZER C3421019: A 26-Week, Phase 2B, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of XXXX Administration in Adults with Obesity  ","PFIZER: A 26-Week, Phase 2B, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of XXXX Administration in Adults with Obesity  "
 ,,
Pain (Acute – Post Operative),,
2024,"CALI BIOSCIENCES CPL-01-301: A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of XXXX in the Management of Postoperative Pain after Open Inguinal Herniorrhaphy.","CALI BIOSCIENCES: A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of XXXX in the Management of Postoperative Pain after Open Inguinal Herniorrhaphy."
2024,"VIATRIS MR-107A-02-TFZ-3001: A Multi-Center, Randomized, Double-Blind, Placebo- (Double Dummy) and Active-Controlled, Parallel-Group Study of XXXX for the Treatment of Acute Postoperative Pain Following Bunionectomy","VIATRIS: A Multi-Center, Randomized, Double-Blind, Placebo- (Double Dummy) and Active-Controlled, Parallel-Group Study of XXXX for the Treatment of Acute Postoperative Pain Following Bunionectomy"
2024,"VIATRIS MR-107A-02-TFZ-3002: A Multi-Center, Randomized, Double-Blind, Placebo- (Double Dummy) and Active-Controlled, Parallel-Group Study of XXXX for the Treatment of Acute Postoperative Pain Following Herniorrhaphy","VIATRIS: A Multi-Center, Randomized, Double-Blind, Placebo- (Double Dummy) and Active-Controlled, Parallel-Group Study of XXXX for the Treatment of Acute Postoperative Pain Following Herniorrhaphy"
2023,"VERTEX VX22-548-104: A Phase 3, randomize, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of XXXX for Acute Pain After a Bunionectomy ","VERTEX: A Phase 3, randomize, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of XXXX for Acute Pain After a Bunionectomy "
2023,"VERTEX VX22-548-107: A Phase 3, Single-arm Study Evaluating the Safety and Effectiveness of XXXX for Acute Pain.  ","VERTEX: A Phase 3, Single-arm Study Evaluating the Safety and Effectiveness of XXXX for Acute Pain.  "
2022,"TEIKOKU PHARMA USA, INC. TPU-DMT-02-2111: A Double-Blind, Placebo-Controlled, Evaluation of the XXXX Transdermal Systems for Postoperative Analgesia Following Abdominoplasty   ","TEIKOKU PHARMA USA, INC.: A Double-Blind, Placebo-Controlled, Evaluation of the XXXX Transdermal Systems for Postoperative Analgesia Following Abdominoplasty   "
2021,"ACADIA PHARMACEUTICALS, INC. ACP-044-004: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXX for Acute Postoperative Pain Following Orthopedic Surgery (Bunionectomy).  ","ACADIA PHARMACEUTICALS, INC.: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXX for Acute Postoperative Pain Following Orthopedic Surgery (Bunionectomy).  "
2021,"CALI PHARMACEUTICALS CPL-01-201: A Randomized, Double-Blind, Placebo- and Active-Controlled, Dose Escalation and Optional Dose Expansion Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of XXXX in the Management of Postoperative Pain After Open Inguinal Herniorrhaphy.","CALI PHARMACEUTICALS: A Randomized, Double-Blind, Placebo- and Active-Controlled, Dose Escalation and Optional Dose Expansion Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of XXXX in the Management of Postoperative Pain After Open Inguinal Herniorrhaphy."
2021,"VERTEX PHARMACEUTICALS VX21-548-101 BUNION: A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of XXXX for Acute Pain After a Bunionectomy.","VERTEX PHARMACEUTICALS: A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of XXXX for Acute Pain After a Bunionectomy."
2020,"VIVOZON, INC. VVZ149-POP-P3-US005: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXX Injections for the Treatment of Postoperative Pain Following Bunionectomy  ","VIVOZON, INC.: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXX Injections for the Treatment of Postoperative Pain Following Bunionectomy  "
2019,"Heron HTX-011-304: A Phase 3b, Randomized, Open-Label Study of XXXXX as the Foundation of a Non-opioid, Multimodal Analgesic Regimen to Decrease Opioid Use Following Unilateral Open Inguinal Herniorrhaphy.","Heron: A Phase 3b, Randomized, Open-Label Study of XXXXX as the Foundation of a Non-opioid, Multimodal Analgesic Regimen to Decrease Opioid Use Following Unilateral Open Inguinal Herniorrhaphy."
2019,"Taiwan TLC 590A1002: entitled 'A Phase 2, Randomized, Double-blind, Comparator- and Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Efficacy o XXXXX for Postsurgical Pain Management Following Bunionectomy' ('Protocol') to be conducted at Institution ('Trial') to involve patients participating in the Trial ('Trial Subjects')   ","Taiwan: entitled 'A Phase 2, Randomized, Double-blind, Comparator- and Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Efficacy o XXXXX for Postsurgical Pain Management Following Bunionectomy' ('Protocol') to be conducted at Institution ('Trial') to involve patients participating in the Trial ('Trial Subjects')   "
2019,"Vertex VX18-150-104: A Phase 2-4, Dose-Ranging Study to Evaluate Efficacy and Safety of XXXXX in Subjects With Acute Pain Following Bunionectomy. ","Vertex: A Phase 2-4, Dose-Ranging Study to Evaluate Efficacy and Safety of XXXXX in Subjects With Acute Pain Following Bunionectomy. "
2019,"Vivozon VVZ149-POP-P2-US004: A Phase 2-4, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXXX Injections for the Treatment of Postoperative Pain Following Bunionectomy. ","Vivozon: A Phase 2-4, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXXX Injections for the Treatment of Postoperative Pain Following Bunionectomy. "
2019,"Vivozon VVZ149-POP-P3-US003: A Phase 2-4, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXXX Injections for the Treatment of Postoperative Pain Following Abdominoplasty. ","Vivozon: A Phase 2-4, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXXX Injections for the Treatment of Postoperative Pain Following Abdominoplasty. "
Vaccine,,
2025,"PFIZER C4591081: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluatiing the Safety, Tolerability, Immunogencity and Efficacy of a Variant-Adapted BNT162b2 Vaccine in Healthy Participants 50 Through 64 Years of Age","PFIZER: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluatiing the Safety, Tolerability, Immunogencity and Efficacy of a Variant-Adapted XXX Vaccine in Healthy Participants 50 Through 64 Years of Age"
2024,"ICOSAVAX ICVX-12-202-RSV: A Phase 2, Randomized, Modified Double-Blind, Active Controlled Study to Characterize the Safety and Immunogenicity of XXXX in Adults 60 Years of Age and older.","ICOSAVAX: A Phase 2, Randomized, Modified Double-Blind, Active Controlled Study to Characterize the Safety and Immunogenicity of XXXX in Adults 60 Years of Age and older."
2024,"ICOSAVAX D8610C00001: A Phase 3, Global, Randomized, Modified Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of IVX-A12, a Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Virus-Like Particle (VLP) Vaccine, in adults 60 Years of Age and Older","ICOSAVAX: A Phase 3, Global, Randomized, Modified Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of XXX, a Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Virus-Like Particle (VLP) Vaccine, in adults 60 Years of Age and Older"
2023,"MODERNA THERAPEUTICS mRNA-1283-P301: A Random, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of XXXX Administered as a Booster Dose Compared with XXXX in Participants Aged 12 Years and Older for the Prevention of COVID-19   ","MODERNA THERAPEUTICS: A Random, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of XXXX Administered as a Booster Dose Compared with XXXX in Participants Aged 12 Years and Older for the Prevention of COVID-19   "
2022,"PFIZER 4781004:  A Phase 3, Randomized, Observer-Blinded Study to Evaluate the Efficacy, Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age or Older  ","PFIZER:  A Phase 3, Randomized, Observer-Blinded Study to Evaluate the Efficacy, Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age or Older  "
2022,"PFIZER C4591044: An Interventional, Randomized, Active-Controlled, Phase 2 Observer-Blind Study to Investigate the Safety, Tolerability, and Immunogenicity of a Bivalent XXXX RNA-Based Vaccine Candidate as a Booster Dose in Covid-19 Vaccine-Experienced Healthy Adults.","PFIZER: An Interventional, Randomized, Active-Controlled, Phase 2 Observer-Blind Study to Investigate the Safety, Tolerability, and Immunogenicity of a Bivalent XXXX RNA-Based Vaccine Candidate as a Booster Dose in Covid-19 Vaccine-Experienced Healthy Adults."
2021,"JANSSEN VAC31518COV3003: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate XX Dose Levels of XXXX Administered as a Two-dose Schedule in Healthy Adults.","JANSSEN: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate XX Dose Levels of XXXX Administered as a Two-dose Schedule in Healthy Adults."
,,
2021,"JANSSEN VAC31518COV2008: A Randomized, Double-blind, Phase 2 Study to Evaluate the Immunogenicity, Reactogenicity and Safety of XXXX Administered as Booster Vaccination in Adults 18 Years of Age and Older Who Have Previously Received Primary Vaccination with XXXX or XXXX. ","JANSSEN: A Randomized, Double-blind, Phase 2 Study to Evaluate the Immunogenicity, Reactogenicity and Safety of XXXX Administered as Booster Vaccination in Adults 18 Years of Age and Older Who Have Previously Received Primary Vaccination with XXXX or XXXX. "
2021,"PFIZER B7471026: A Phase 3, Randomized, Double-Blind Trial to Describe the Safety and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine When Co-administered With A Booster Dose of XXXX in Adults 65 Years of Age and Older.","PFIZER: A Phase 3, Randomized, Double-Blind Trial to Describe the Safety and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine When Co-administered With A Booster Dose of XXXX in Adults 65 Years of Age and Older."
2021,"PFIZER C4591020: A Phase 3, Randomized, Observer-Blind Study To Evaluate The Safety, Tolerability And Immunogenicity Of A Lyophilized Formulation Of The Vaccine Candidate XXXX Against Covid-19 In Healthy Adults 18 Through 55 Years Of Age. ","PFIZER: A Phase 3, Randomized, Observer-Blind Study To Evaluate The Safety, Tolerability And Immunogenicity Of A Lyophilized Formulation Of The Vaccine Candidate XXXX Against Covid-19 In Healthy Adults 18 Through 55 Years Of Age. "
2021,PFIZER C4591031: A Phase 3 Master Protocol To Evaluate Additional Dose(S) Of XXXX In Healthy Individuals Previously Vaccinated With XXXX. ,PFIZER: A Phase 3 Master Protocol To Evaluate Additional Dose(S) Of XXXX In Healthy Individuals Previously Vaccinated With XXXX. 
2020,"JANSSEN VAC31518COV3001: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of XXXX for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older  ","JANSSEN: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of XXXX for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older  "
2020,"PFIZER C4591001: A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of XXXX Vaccine Candidates Against COVID-19 in Healthy Adults.","PFIZER: A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of XXXX Vaccine Candidates Against COVID-19 in Healthy Adults."
2019,"Pfizer B7471006: A Phase 3, Randomized, Open-Label Trial to Evaluate The Safety and Immunogenicity of A 20-Valent Pneumococcal Conjugate Vaccine in Adults >= 65 Years of Age with Prior Pneumococcal Vaccination.","Pfizer: A Phase 3, Randomized, Open-Label Trial to Evaluate The Safety and Immunogenicity of A 20-Valent Pneumococcal Conjugate Vaccine in Adults >= 65 Years of Age with Prior Pneumococcal Vaccination."
2019,"Pfizer B7471007: A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20 - Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine - Naïve Adults 18 Years of Age and Older.  ","Pfizer: A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20 - Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine - Naïve Adults 18 Years of Age and Older.  "
2019,"Pfizer B7471008: A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine - Naïve Adult 18 Through 49 Years of Age. ","Pfizer: A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine - Naïve Adult 18 Through 49 Years of Age. "
2019,"Pfizer B7931023: A Phase 2B, Randomized, Double Blind, Vehicle Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of XXXXX Topical Cream Applied Once or Twice Daily for 12 Weeks in Participants with Mild or Moderate Chronic Plaque Psoriasis. ","Pfizer: A Phase 2B, Randomized, Double Blind, Vehicle Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of XXXXX Topical Cream Applied Once or Twice Daily for 12 Weeks in Participants with Mild or Moderate Chronic Plaque Psoriasis. "
2019,"Pfizer C1061011: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel Group Study to Evaluate Safety, Tolerability and Pharmacodynamics of XXXXX Administered Daily for 16 Weeks in Adults with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus on Metformin.","Pfizer: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel Group Study to Evaluate Safety, Tolerability and Pharmacodynamics of XXXXX Administered Daily for 16 Weeks in Adults with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus on Metformin."
 ,,
2019,"Pfizer C2501004: A Phase 2, Randomized, Double Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of XXXXX in Participants with Moderate to Severe Plaque Psoriasis. ","Pfizer: A Phase 2, Randomized, Double Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of XXXXX in Participants with Moderate to Severe Plaque Psoriasis. "
 ,,
2019,"Takeda DEN-307: An Open-Label, Phase 3 Trial to Investigate the Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) at the End of Shelf Life in Healthy Adults in Non-Endemic Country(ies) for Dengue. ","Takeda: An Open-Label, Phase 3 Trial to Investigate the Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) at the End of Shelf Life in Healthy Adults in Non-Endemic Country(ies) for Dengue. "
 ,,
Other Indication,,
2024,"METSERA MET097-24-201: A Phase 2b, Multi-Center, Randomized, Placebo controlled Double-Blind Study to Investigate the Safety and Efficacy of 16 Weeks of Four Different Regimens of Once-Weekly Met097 in Participants with Obesity or Overweight","METSERA: A Phase 2b, Multi-Center, Randomized, Placebo controlled Double-Blind Study to Investigate the Safety and Efficacy of 16 Weeks of Four Different Regimens of Once-Weekly XXX in Participants with Obesity or Overweight"
2020,"NOVAVAX, INC. 2019nCoV-301: A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a XXXX (XXXX) with XXXX Adjuvant in Adult Participants ≥ 18 years.   ","NOVAVAX, INC.: A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a XXXX (XXXX) with XXXX Adjuvant in Adult Participants ≥ 18 years.   "
 ,,
2020,"UPSHER-SMITH LABS P361-502: A Phase 4, Open-Label, Single-Arm Study to Evaluate the Effects of XXXX on 24-hour Ambulatory Blood Pressure Monitoring in Hypogonadal Men Using Therapeutic Testosterone Replacement Therapy.","UPSHER-SMITH LABS: A Phase 4, Open-Label, Single-Arm Study to Evaluate the Effects of XXXX on 24-hour Ambulatory Blood Pressure Monitoring in Hypogonadal Men Using Therapeutic Testosterone Replacement Therapy."
 ,,
2019,"Janssen VAC18193RSV2001: A Phase 2b, Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy, Immunogenicity and Safety of an XXX-based Regimen in the Prevention of XXX-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older.  ","Janssen: A Phase 2b, Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy, Immunogenicity and Safety of an XXX-based Regimen in the Prevention of XXX-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older.  "
,,
,,
 ,,
 ,,
